Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copies of the newspaper advertisement titled 'Consolidated financial results for quarter and year ended March 31, 2023'. The advertisements appeared in Business Standard and Pratahkal (Marathi version). Solara Active Pharma Sciences Ltd - 541540 - Disclosure Of Related Party Transactions
In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021, we hereby enclose disclosure on Related Party Transactions, for the second half year ended March 31, 2023
Solara Active Pharma Sciences Results Earnings Call for Q4FY23
Conference Call with Solara Active Pharma Sciences Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript. Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 and 46 read with clause 15 of Para A of Part A of Schedule Ill of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that we have uploaded audio recording of the Q4 of FY23 Earnings Call held on May 12, 2023, on our Company website under the heading Investor relations/Stock Exchange Communication/ Investor update. Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ('Listing Regulations'), we wish to inform that based on the recommendation of the Audit Committee, the Board of Directors of the Company at its meeting held today, i.e. May 12, 2023, has, subject to the approval of the members of the Company to be obtained in the ensuing Annual general meeting of the Company, recommended the re-appointment of Deloitte Haskins & Sells LLP, Chartered Accountants (Firm Registration Number: 117366W/W-100018) as the Statutory Auditors of the Company under Section 139 of the Companies Act 2013. Q4FY23 Quarterly & FY23 Annual Result Announced for Solara Active Pharma Sciences Ltd.
Pharmaceuticals company Solara Active Pharma Sciences announced Q4FY23 & FY23 results: FY23 Revenues at Rs 14,663 million up 14% YoY; EBITDA at Rs 1,507 million up 63% YoY Q4FY23 Revenues stood at Rs 3,853 million Gross margins at 50.3% in Q4FY23 versus 47.3% in Q3FY23; QoQ Improvement in Gross margins by 300 bps Reported EBITDA at Rs 515 million, EBITDA margins at 13.4%; QoQ Improvement in EBITDA margins by 70 bps Reduction in under-recoveries at Vizag Commenting on the financial performance, Jitesh Devendra, MD of the company, remarked, “We are delighted to conclude fiscal year 23 on a positive note, having accomplished many of the goals we set for ourselves at the beginning of the year. The prior fiscal year (FY22) was a difficult one for the company, prompting the board to make several important decisions to ensure Solara returns to positive growth territory with sustained profitability. We had set forth key strategic priorities, which included resetting and concentrating the base business, restoring R&D; velocity, addressing under-recoveries at our newly commissioned Vizag site, and expanding into new products and geographies. I am pleased to report that we are trending positively toward a broad range of outcomes, and our performance in FY23, particularly the second half, is indicative of the company's efforts to rebound. Additionally, to the FY23 results, we have made major strides toward founding a strong base, yielding even greater future performance as we keep expanding. As we enter FY24, we are extremely optimistic about the business's prospects. We are confident that Solara will have another successful year. We remain committed to delivering value and thank our investors for their continued support.” Commenting on the financial performance, Poorvank Purohit, CEO of the company, remarked “I am delighted to join Solara and be part of Solara’s 3.0 growth journey. These improved financial results are a testament to the hard work and dedication of our employees and the strength of our product portfolio. Moving forward, we will continue to focus on outcomes that deliver value to all our stakeholders. The second half of Fiscal year 2023 has brought in more confidence in the fundamentals of the business. Our margins have risen, and we are working towards building new opportunities for sustainable growth.” Result PDF Solara Active Pharma Sciences Ltd - 541540 - Outcome Of Board Meeting For The Quarter And Year Ended March 31, 2023
Audited financial results (standalone and consolidated) of the Company for the quarter and Year ended March 31, 2023, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. A copy of the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2023, along with the Auditors report for the said period and press release on the same is attached. Solara Active Pharma Sciences Ltd - 541540 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Solara Active Pharma Sciences Ltd 2 CIN NO. L24230MH2017PLC291636 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2022-23, 2023-24 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2021-22, 2022-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-S Murali KrishnaDesignation :-Company Secretary Name of the Chief Financial Officer :- S Hariharan Designation : -Executive Director and CFO Date: 06/05/2023
